Please assess the completion status of the following clinical trial:

Trial Title: Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must sign an informed consent before of specific procedures of clinical trial.~* Patients with histologically confirmed breast cancer and overexpression of Her2neu.~* Age\> 18 years.~* Eastern Cooperative Oncology Group (ECOG) equal or \< 2.~* Patients have not been treated previously with chemotherapy for metastatic disease.~* Patients must have at least one measurable lesion according to RECIST criteria.~* Patients should have an adequate organ function to tolerate chemotherapy.~Exclusion Criteria:~* Patients with hypersensitivity reactions to any of the medications of the clinical trial.~* Patients who are pregnant or lactating are not eligible.~* Hepatic disease.~* Not controlled active infection~* Symptomatic metastatic brain cancer~* Previous adjuvant treatment with anthracyclines with a total accumulated dose \> 300 mg/m2 (Doxorubicin) or \> 600 mg/m2 (Epirubicin)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Caelyx,Cyclophosphamide,Trastuzumab (Type: OTHER): Caelyx (Liposomal Doxorubicin) 50 mg/m2 every 4 weeks for 6 cycles, Cyclophosphamide 600 mg/m2 every 4 weeks for 6 cycles, Trastuzumab weekly for 24 weeks, at dose of 2mg/kg (day 1 loading dose of 4mg/kg)

Based on this trial design, predict the completion outcome and termination type (if applicable).